Novartis: Pulmonary Arterial Hypertension trials
The registry lists 12 Pulmonary Arterial Hypertension studies with Novartis as lead sponsor. 1 are open to participants now and 11 have results posted.
Phase 1 1Phase 2 7Phase 3 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)RecruitingNCT06649110Phase 1/2
- Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension ParticipantsTerminatedNCT05764265Phase 2Results posted
- Study of Efficacy and Safety of LTP001 in Pulmonary Arterial HypertensionTerminatedNCT05135000Phase 2Results posted
- Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH PatientsTerminatedNCT02939599Phase 2Results posted
- Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH PatientsTerminatedNCT02927366Phase 2Results posted
- Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in JapanCompletedNCT02042014Phase 3Results posted
- Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)TerminatedNCT01392495Phase 3Results posted
- Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension ParticipantsCompletedNCT01392469Phase 3Results posted
- Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)TerminatedNCT01179737Phase 2Results posted
- Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)TerminatedNCT01117987Phase 3Results posted
- Imatinib (QTI571) in Pulmonary Arterial HypertensionCompletedNCT00902174Phase 3Results posted
- Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial HypertensionCompletedNCT00477269Phase 2/3Results posted